An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
Latest Information Update: 29 May 2024
At a glance
- Drugs NNZ 2591 (Primary)
- Indications Pitt-Hopkins syndrome
- Focus Adverse reactions; Pharmacokinetics
- Acronyms PTHS-001
- Sponsors Neuren Pharmaceuticals
- 27 May 2024 Results published in the Neuren Pharmaceuticals Media Release
- 05 Dec 2023 According to a Neuren Pharmaceuticals media release, top-line results from the trial are expected to be available in Q2 2024.
- 03 Aug 2023 Planned End Date changed from 18 May 2023 to 30 Apr 2024.